[Cooperative phase II study of spansule tegafur (SF-SP)].
A phase II study of oral administration of SF-SP alone was conducted in 187 patients with advanced cancers involving 34 institutions in Kinki area. CR was observed in one case of breast cancer, and PR in 29 cases. In 7 responders, response durations of 6 months or more were observed. The drug was effective against colo-rectal, in particular, gastric and breast cancer. No serious toxicity was observed.
D000284:Administration, Oral; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy; D002214:Capsules; D003110:Colonic Neoplasms / Q000188:drug therapy; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D012004:Rectal Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy; D005641:Tegafur / Q000627:therapeutic use*
D002214:Capsules; D003692:Delayed-Action Preparations; D005641:Tegafur; D005472:Fluorouracil